Lung cancer remains the most frequently diagnosed malignancy and the leading cause of cancer tumour-related mortality ...

(Denver, Colo—October 6, 2025) Invasive lung squamous cell carcinoma (LUSC) accounts for approximately one-quarter of all lung cancers, but therapeutic options for LUSC remain limited, primarily due ...

Sac-TMT combined with Keytruda significantly improves progression-free survival in PD-L1-positive advanced non-small cell ...

The U.S. Food and Drug Administration said on Wednesday that it has approved Bayer's drug for patients with a form of lung ...

Approximately 20% of new lung cancer diagnoses occur in nonsmokers in the U.S., according to The Ohio State University ...

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative ...